Rapport Therapeutics announced the pricing of its underwritten public offering of 9,615,385 shares of common stock at a public offering price of $26.00 per share. The gross proceeds from this offering are expected to be approximately $250.0 million, before deducting underwriting discounts and commissions and other offering expenses.
The company has also granted the underwriters a 30-day option to purchase up to an additional 1,442,307 shares of its common stock at the public offering price. The offering is anticipated to close on or about September 11, 2025, subject to customary closing conditions.
This capital infusion follows the recent announcement of positive topline Phase 2a results for RAP-219 in focal onset seizures. The funds are intended to support the advancement of RAP-219 into Phase 3 pivotal trials and further development of Rapport's precision neuroscience pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.